QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NASDAQ:EVLO

Evelo Biosciences (EVLO) Stock Forecast, Price & News

$3.63
-0.12 (-3.20%)
(As of 10/3/2023 ET)
Compare
Today's Range
$3.55
▼
$3.90
50-Day Range
$3.63
▼
$13.31
52-Week Range
$0.49
▼
$48.40
Volume
58,998 shs
Average Volume
384,753 shs
Market Capitalization
$68.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.33
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Evelo Biosciences MarketRank™ Forecast

Analyst Rating
Reduce
1.75 Rating Score
Upside/​Downside
1,644.7% Upside
$63.33 Price Target
Short Interest
Healthy
2.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$12.50 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($6.70) to ($3.04) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

537th out of 976 stocks

Pharmaceutical Preparations Industry

244th out of 447 stocks

See Top Rated MarketRank™ Stocks Here

EVLO stock logo

About Evelo Biosciences (NASDAQ:EVLO) Stock

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

EVLO Price History

EVLO Stock News Headlines

August 18, 2023 | seekingalpha.com
Evelo Biosciences down 39% as 13M share offering begins
August 14, 2023 | finanznachrichten.de
Evelo Biosciences, Inc.: Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
October 3, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
August 14, 2023 | finance.yahoo.com
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
August 11, 2023 | finance.yahoo.com
FMR LLC Acquires Significant Stake in Evelo Biosciences Inc
July 27, 2023 | msn.com
Morgan Stanley Maintains Evelo Biosciences (EVLO) Equal-Weight Recommendation
July 21, 2023 | benzinga.com
Why Are velo Biosciences Stock Is Trading Higher Today?
July 21, 2023 | benzinga.com
Why Are Evelo Biosciences Stock Is Trading Higher Today?
October 3, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
July 21, 2023 | theglobeandmail.com
Instrument Name Evelo Biosciences Inc Instrument Symbol (EVLO-Q)
July 12, 2023 | finance.yahoo.com
Evelo Biosciences Closes $25.5 Million Private Placement
July 11, 2023 | benzinga.com
Evelo Biosciences shares are trading higher after the company announced a $25.5 million private placement.
July 10, 2023 | marketwatch.com
Evelo Biosciences Shares Rise 20% After Private Offering Prices
July 10, 2023 | msn.com
Evelo Biosciences Plans $25.5M Private Placement To Fund Psoriasis Trial, Pay Down Debt
July 10, 2023 | finance.yahoo.com
Evelo Biosciences Announces $25.5 Million Private Placement
June 30, 2023 | finanznachrichten.de
Evelo Biosciences, Inc.: Evelo Biosciences Announces Reverse Stock Split Effective
June 29, 2023 | msn.com
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 29, 2023 | finance.yahoo.com
Evelo Biosciences Announces Reverse Stock Split Effective
June 22, 2023 | finance.yahoo.com
EVLO - Evelo Biosciences, Inc.
June 20, 2023 | investorplace.com
Why Is Evelo Biosciences (EVLO) Stock Up 51% Today?
June 15, 2023 | benzinga.com
Evelo Biosciences Granted U.S. Patent #11672834 For "PREBIOTIC COMPOSITIONS AND METHODS OF USE THEREOF FOR MODULATION OF THE MICROBIOME"
May 17, 2023 | finance.yahoo.com
What Makes Evelo Biosciences, Inc. (EVLO) a New Buy Stock
May 10, 2023 | finance.yahoo.com
Evelo Biosciences Insiders Added US$575k Of Stock To Their Holdings
May 10, 2023 | finance.yahoo.com
Evelo Biosciences Insiders Added US$575k Of Stock To Their Holdings \
April 27, 2023 | markets.businessinsider.com
Evelo Biosciences (EVLO) Gets a Hold from Morgan Stanley
April 27, 2023 | investorplace.com
Why Is Evelo Biosciences (EVLO) Stock Up 78% Today?
April 26, 2023 | finance.yahoo.com
Flagship-backed startup makes layoffs for second time in three months
See More Headlines
Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Company Calendar

Last Earnings
8/14/2023
Today
10/03/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVLO
CUSIP
N/A
CIK
1694665
Web
www.evelobio.com
Phone
(617) 577-0300
Fax
N/A
Employees
66
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$63.33
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+1,644.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($18.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-114,530,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-3,491.73%
Return on Assets
-154.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.53
Quick Ratio
0.53

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.92) per share
Price / Book
-3.95

Miscellaneous

Outstanding Shares
18,830,000
Free Float
18,082,000
Market Cap
$68.35 million
Optionable
Not Optionable
Beta
1.71
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Balkrishan Gill Ph.D. (Age 58)
    Pres, CEO & Director
  • Ms. Marella Thorell (Age 56)
    CFO, Sr. VP, Principal Financial Officer, Principal Accounting Officer & Treasurer
    Comp: $530.45k
  • Dr. Chun Zhang Ph.D.
    Chief Technical Operations & Quality Officer
  • Dr. Mark Bodmer Ph.D. (Age 65)
    Chief Scientific Officer and Pres of R&D
  • Ms. Jessica Cotrone
    VP & Head of Communications
  • Ms. Leslie Wardwell-Scott Ph.D.
    VP and Head of Corp. Devel. & Strategic Integration
  • Dr. Andrea Itano Ph.D.
    Head of Research
  • Dr. Duncan McHale M.D. (Age 56)
    MBBS, Ph.D., Chief Medical Officer
  • Mr. Douglas Maslin
    Sr. Director & Immunology Clinical Lead

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













EVLO Stock - Frequently Asked Questions

Should I buy or sell Evelo Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EVLO shares.
View EVLO analyst ratings or view top-rated stocks.

What is Evelo Biosciences' stock price forecast for 2023?

4 brokers have issued 1-year target prices for Evelo Biosciences' shares. Their EVLO share price forecasts range from $40.00 to $100.00. On average, they anticipate the company's share price to reach $63.33 in the next twelve months. This suggests a possible upside of 1,644.7% from the stock's current price.
View analysts price targets for EVLO or view top-rated stocks among Wall Street analysts.

How have EVLO shares performed in 2023?

Evelo Biosciences' stock was trading at $32.20 at the start of the year. Since then, EVLO stock has decreased by 88.7% and is now trading at $3.63.
View the best growth stocks for 2023 here.

When is Evelo Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our EVLO earnings forecast.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) issued its quarterly earnings data on Monday, August, 14th. The company reported ($3.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.33) by $0.78.

When did Evelo Biosciences' stock split?

Evelo Biosciences shares reverse split on Friday, June 30th 2023. The 1-20 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

How do I buy shares of Evelo Biosciences?

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $3.63.

How much money does Evelo Biosciences make?

Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $68.35 million. The company earns $-114,530,000.00 in net income (profit) each year or ($18.18) on an earnings per share basis.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com.

This page (NASDAQ:EVLO) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -